Summary: Aetna, a CVS Health company, modified CPB 1030 covering retifanlimab-dlwr (Zynyz), effective April 29, 2026. Here's what billing teams need to know before submitting claims.
Aetna updated its retifanlimab-dlwr (Zynyz) coverage policy under CPB 1030 Aetna system. Retifanlimab-dlwr is a PD-1 blocking antibody used in oncology — specifically for Merkel cell carcinoma and certain squamous cell carcinomas. The CPB 1030 Aetna policy modification signals updated medical necessity criteria and potentially revised prior authorization requirements that your billing team needs to review now. This policy does not list specific CPT or HCPCS codes in the available data — we'll address what that means for your charge capture below.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Retifanlimab-dlwr (Zynyz) — CPB 1030 |
| Policy Code | CPB 1030 |
| Change Type | Modified |
| Effective Date | April 29, 2026 |
| Impact Level | High |
| Specialties Affected | Oncology, Hematology/Oncology, Infusion Therapy, Hospital Outpatient |
| Key Action | Pull the current CPB 1030 policy document and compare it against your existing billing guidelines before submitting new Zynyz claims |
Aetna Retifanlimab-dlwr Coverage Criteria and Medical Necessity Requirements 2026
Aetna's retifanlimab-dlwr coverage policy under CPB 1030 governs when Zynyz is reimbursable for Aetna members. Because the full policy detail wasn't available in the source data, the specific criteria language below reflects what billing teams should expect based on FDA approvals and Aetna's standard oncology drug coverage framework — but you must pull the actual CPB 1030 document from Aetna to confirm current criteria before billing.
Retifanlimab-dlwr (Zynyz) received FDA approval for two indications. First: adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Second: adults with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on platinum-based chemotherapy. Aetna's coverage policy for PD-1 inhibitors like Zynyz typically ties medical necessity to these FDA-approved indications and specific clinical parameters.
For medical necessity to be met under most Aetna oncology drug policies, expect criteria like these to apply: the member must have a confirmed histologic diagnosis, disease must be at the required stage or progression point, and the treating oncologist must document prior therapy history. Prior authorization is almost certainly required for Zynyz under CPB 1030 — this is standard for specialty oncology biologics at Aetna. Don't submit a claim without confirming prior auth status first.
The modification to CPB 1030 on April 29, 2026 may reflect expanded indications, updated clinical criteria, or changes to step therapy or concurrent therapy requirements. Until you pull the current document, treat any Zynyz claim as potentially affected. If you're not sure how this change applies to your patient mix, talk to your compliance officer before the effective date passes.
Aetna Retifanlimab-dlwr Exclusions and Non-Covered Indications
The available policy data does not list specific exclusions. That said, Aetna's standard oncology drug coverage policies exclude coverage for off-label indications not supported by recognized compendia like NCCN or DrugDex. Zynyz used outside its FDA-approved indications — or for indications lacking sufficient compendia support — will almost certainly not meet medical necessity under CPB 1030.
Combination regimens not included in the clinical trial data reviewed by Aetna are another common denial trigger for PD-1 inhibitors. If your oncology team is using Zynyz in a combination not explicitly addressed in CPB 1030, flag that scenario for your compliance officer before billing. A claim denial in that context can be difficult to overturn without strong clinical documentation.
Coverage Indications at a Glance
The policy data provided does not include indication-level criteria. The table below reflects known FDA-approved indications for retifanlimab-dlwr and the coverage status billing teams should verify against the current CPB 1030 document.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Metastatic or recurrent locally advanced Merkel cell carcinoma (adults) | Verify against CPB 1030 | Confirm with Aetna | FDA-approved indication — prior auth likely required |
| Locally advanced or metastatic squamous cell carcinoma of the anal canal, after platinum-based chemotherapy (adults) | Verify against CPB 1030 | Confirm with Aetna | FDA-approved indication — prior auth likely required |
| Off-label oncology use | Not Covered (standard Aetna position) | N/A | Must have NCCN or compendia support; document thoroughly |
Confirm every row against the live CPB 1030 document. The April 29, 2026 modification may have added or adjusted these statuses.
Aetna Retifanlimab-dlwr Billing Guidelines and Action Items 2026
The effective date of April 29, 2026 means this policy is already active. If your practice bills Zynyz to Aetna, these are your action items now.
| # | Action Item |
|---|---|
| 1 | Pull the current CPB 1030 document immediately. Go to app.payerpolicy.org/p/aetna/1030 or Aetna's provider portal. Read the full coverage criteria, not just the summary. Do this before your next Zynyz claim. |
| 2 | Confirm prior authorization requirements for all active Zynyz patients. Prior auth for PD-1 inhibitors at Aetna is standard. Any patient currently on Zynyz whose auth was issued before April 29, 2026 may need reauthorization under the updated criteria. Call Aetna's specialty pharmacy or oncology PA line to confirm. |
| 3 | Update your retifanlimab-dlwr billing guidelines internally. Share the CPB 1030 changes with your oncology billing team, infusion nurses who document treatment, and any prior auth coordinators. The change is live — your internal processes need to match. |
| 4 | Audit open Zynyz claims with dates of service on or after April 29, 2026. Any claim submitted under the old criteria that doesn't meet the new standard is a denial risk. Review those claims now, before remittance comes back. |
| 5 | Document medical necessity thoroughly on every claim. Aetna's oncology drug policies require clinical documentation that maps directly to coverage criteria. This means histologic diagnosis, prior treatment history, current disease stage, and the treating oncologist's rationale. Thin documentation is the fastest path to a claim denial. |
| 6 | Check the HCPCS code for retifanlimab-dlwr. The available policy data does not list specific HCPCS codes. Retifanlimab-dlwr billing typically uses a J-code or Q-code assigned after FDA approval. Confirm the correct HCPCS code with your drug compendia, the Aetna fee schedule, or your specialty pharmacy. Using an incorrect or unrecognized code will cause a denial regardless of prior auth status. |
| 7 | Flag any combination therapy regimens for compliance review. If Zynyz is being used in combination with carboplatin or other agents, verify that Aetna's updated CPB 1030 addresses that combination. If it doesn't, get your compliance officer and billing consultant involved before the claim goes out. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Retifanlimab-dlwr Under CPB 1030
The CPB 1030 policy data provided does not list specific CPT, HCPCS, or ICD-10 codes. Do not assume codes based on similar drugs or older policy versions.
HCPCS Codes — Action Required
Retifanlimab-dlwr (Zynyz) billing requires the correct HCPCS J-code or Q-code. These codes are assigned by CMS after FDA approval and may be updated on the quarterly HCPCS fee schedule. Confirm the active code through:
- CMS HCPCS code lookup at cms.gov
- Your specialty pharmacy's billing documentation
- Aetna's drug reimbursement fee schedule or formulary tool
- Your drug compendia (Medi-Span, Red Book, or equivalent)
Using an outdated or unrecognized code is one of the most common denial causes for specialty oncology drugs. Verify the code is active and Aetna-recognized before the claim goes out.
ICD-10-CM Diagnosis Codes — Verify Against CPB 1030
No ICD-10 codes were included in the policy data. Based on FDA-approved indications, the diagnosis codes most likely to appear in CPB 1030 include Merkel cell carcinoma and anal canal squamous cell carcinoma diagnoses. Confirm the exact codes Aetna requires by pulling the full CPB 1030 document. Submitting with an unsupported diagnosis code is a direct path to medical necessity denial.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.